Iovance Biotherapeutics Inc - Company Profile
Powered by
All the data and insights you need on Iovance Biotherapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Iovance Biotherapeutics Inc Strategy Report
- Understand Iovance Biotherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Iovance Biotherapeutics Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
WO2022187741A2 | Application | TUMOR STORAGE AND CELL CULTURE COMPOSITIONS | A01N1/0215; A01N1/0221; A01N1/0226; A01P1/00; A61K35/17; C12N5/0636; C12N5/0693 | September 09, 2022 |
US11433097B2 | Grant | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma | A61K35/00; A61K35/17; A61P35/04; C12N2501/04; C12N2501/2302; C12N2501/515; C12N2502/30; C12N5/0634; C12N5/0638; G01N2333/522; G01N33/574 | September 06, 2022 |
EP4048295A1 | Application | GENBEARBEITUNG VON TUMORINFILTRIERENDEN LYMPHOZYTEN UND DEREN VERWENDUNGEN IN DER IMMUNTHERAPIE | A61K2039/5156; A61K2039/5158; A61K35/17; A61K39/0011; C12N15/907; C12N2501/2302; C12N2501/2315; C12N2501/2321; C12N2501/603; C12N5/0638 | August 31, 2022 |
JP7125392B2 | Grant | レムナント腫瘍浸潤リンパ球並びにそれを調製及び使用する方法 | A61K2039/5158; A61K31/661; A61K35/17; A61K38/2013; A61K39/0011; A61P35/00; A61P35/02; C12N2501/06; C12N2501/065; C12N2501/2302; C12N2501/2304; C12N2501/2307; C12N2501/2315; C12N2501/2321; C12N2501/515; C12N2501/599; C12N2501/998; C12N5/0638 | August 24, 2022 |
WO2022170219A1 | Application | ADJUVANT THERAPY FOR CANCER | A61K35/17; A61N1/327; A61N1/36002; A61N1/40; A61P35/00; C12N2501/23; C12N5/0636 | August 11, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer